Yimei Li

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1948904/publications.pdf

Version: 2024-02-01

236925 276875 2,363 149 25 41 citations h-index g-index papers 151 151 151 4007 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Variation in hospital costs and resource utilisation after congenital heart surgery. Cardiology in the Young, 2023, 33, 420-431.	0.8	3
2	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. Leukemia, 2022, 36, 283-287.	7.2	17
3	Arterial spin labeling as an ancillary assessment to postoperative conventional angiogram in pediatric moyamoya disease. Journal of Neurosurgery: Pediatrics, 2022, 29, 40-47.	1.3	1
4	Center Variation in Indication and Short-Term Outcomes after Pediatric Heart Transplantation: Analysis of a Merged United Network for Organ Sharing – Pediatric Health Information System Cohort. Pediatric Cardiology, 2022, 43, 636-644.	1.3	1
5	Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CARÂT-cell therapy. Blood, 2022, 139, 2173-2185.	1.4	39
6	Outcomes of children and young adults with Tâ€ell acute lymphoblastic leukemia/lymphoma who present in critical status. Pediatric Blood and Cancer, 2022, 69, e29457.	1.5	2
7	Association between timely targeted treatment and outcomes in patients with metastatic HER2â€overexpressing gastroesophageal adenocarcinoma. Cancer, 2022, , .	4.1	O
8	Unrelated donor \hat{l} ±/ \hat{l} ² T cell– and B cell–depleted HSCT for the treatment of pediatric acute leukemia. Blood Advances, 2022, 6, 1175-1185.	5.2	9
9	Reduced ER–mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO Journal, 2022, 41, e108272.	7.8	16
10	Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. Journal of Clinical Oncology, 2022, 40, 945-955.	1.6	79
11	Late effects in survivors of highâ€risk neuroblastoma following stem cell transplant with and without total body irradiation. Pediatric Blood and Cancer, 2022, 69, e29537.	1.5	8
12	Sociodemographics, Health Competence, and Transition Readiness Among Adolescent/Young Adult Cancer Survivors. Journal of Pediatric Psychology, 2022, 47, 1096-1106.	2.1	6
13	Progression-free survival and patterns of response in patients with high-risk neuroblastoma (HR-NB) treated with irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSFS) chemoimmunotherapy Journal of Clinical Oncology, 2022, 40, 10025-10025.	1.6	1
14	Impact of socioeconomic status on survival after CD19 CART therapy Journal of Clinical Oncology, 2022, 40, 7013-7013.	1.6	0
15	Thyroid gland definitive ultrasound screening in childhood cancer survivors following radiotherapy Journal of Clinical Oncology, 2022, 40, 10049-10049.	1.6	O
16	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clinical Cancer Research, 2022, 28, 3940-3949.	7.0	4
17	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatric Blood and Cancer, 2021, 68, e28315.	1.5	1
18	Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma. Journal of the National Cancer Institute, 2021, 113, 282-291.	6.3	33

#	Article	IF	CITATIONS
19	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 177.e1-177.e8.	1.2	16
20	Daily text message assessments of 6â€mercaptopurine adherence and its proximal contexts in adolescents and young adults with leukemia: A pilot study. Pediatric Blood and Cancer, 2021, 68, e28767.	1.5	10
21	The firstâ€order Markov conditional linear expectation approach for analysis of longitudinal data. Statistics in Medicine, 2021, 40, 1972-1988.	1.6	O
22	Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial. Journal of Clinical Oncology, 2021, 39, 920-930.	1.6	110
23	Adherence to and determinants of guidelineâ€recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice. Cancer, 2021, 127, 2562-2570.	4.1	2
24	Association between timely targeted therapy initiation and clinical outcomes in patients with advanced HER2+ gastroesophageal adenocarcinoma Journal of Clinical Oncology, 2021, 39, e16048-e16048.	1.6	0
25	Electronic symptom monitoring in pediatric patients hospitalized for chemotherapy. Cancer, 2021, 127, 2980-2989.	4.1	17
26	A GPC2 antibody-drug conjugate is efficacious against neuroblastoma and small-cell lung cancer via binding a conformational epitope. Cell Reports Medicine, 2021, 2, 100344.	6.5	14
27	The predictive value of PNH clones, 6p CN-LOH, and clonal TCR gene rearrangement for aplastic anemia diagnosis. Blood Advances, 2021, 5, 3216-3226.	5.2	21
28	Understanding Adolescent and Young Adult 6-Mercaptopurine Adherence and mHealth Engagement During Cancer Treatment: Protocol for Ecological Momentary Assessment. JMIR Research Protocols, 2021, 10, e32789.	1.0	5
29	A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma. Frontiers in Oncology, 2021, 11, 744739.	2.8	5
30	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2021, 39, 3044-3055.	1.6	94
31	CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. Lancet Haematology,the, 2021, 8, e711-e722.	4.6	57
32	Outcomes of intensification of induction chemotherapy for children with highâ€risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e29281.	1.5	6
33	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 2021, 4, e2128385.	5.9	6
34	Evaluation of an automated pediatric malnutrition screen using anthropometric measurements in the electronic health record: a quality improvement initiative. Supportive Care in Cancer, 2020, 28, 1659-1666.	2.2	8
35	Feasibility and acceptability of a pilot tailored text messaging intervention for adolescents and young adults completing cancer treatment. Psycho-Oncology, 2020, 29, 164-172.	2.3	21
36	Partially CD3+-Depleted Unrelated and Haploidentical Donor Peripheral Stem Cell Transplantation Has Favorable Graft-versus-Host Disease and Survival Rates in Pediatric Hematologic Malignancy. Biology of Blood and Marrow Transplantation, 2020, 26, 493-501.	2.0	3

#	Article	IF	CITATIONS
37	Role of Metastatic Site Irradiation in Pediatric Patients With Metastatic Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2020, 42, e305-e309.	0.6	3
38	PAâ€CRM: A continuous reassessment method for pediatric phase I oncology trials with concurrent adult trials. Biometrics, 2020, 76, 1364-1373.	1.4	8
39	Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma. Pediatric Blood and Cancer, 2020, 67, e28267.	1.5	16
40	CD19-targeted chimeric antigen receptor (CAR) T cells in CNS relapsed acute lymphoblastic leukemia (ALL) Journal of Clinical Oncology, 2020, 38, 10511-10511.	1.6	15
41	MBCL-14. A STUDY OF LOW-DOSE CRANIOSPINAL RADIATION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AVERAGE-RISK MEDULLOBLASTOMA. Neuro-Oncology, 2020, 22, iii390-iii391.	1.2	0
42	Assessment of the impact of inpatient infectious events in pediatric patients with newly diagnosed acute leukemia at Dr. Robert Reid Cabral Children's Hospital, Dominican Republic. PLoS ONE, 2020, 15, e0243795.	2.5	1
43	Perioperative near-infrared spectroscopy cerebral oxygen saturation in symptomatic pediatric hydrocephalus patients at risk for intracranial hypertension. Journal of Neurosurgery: Pediatrics, 2020, 25, 235-241.	1.3	6
44	Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice Journal of Clinical Oncology, 2020, 38, 12-12.	1.6	0
45	Germline <i>POT1</i> Variants Can Predispose to a Variety of Hematologic Neoplasms. Blood, 2020, 136, 2-4.	1.4	1
46	Tumor bed proton irradiation in young children with localized medulloblastoma. Pediatric Blood and Cancer, 2019, 66, e27972.	1.5	4
47	Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications, 2019, 15, 100379.	1.1	8
48	Changes Over Time in Good-Parent Beliefs Among Parents of Children With Serious Illness: A Two-Year Cohort Study. Journal of Pain and Symptom Management, 2019, 58, 190-197.	1.2	39
49	Evaluation of the Pediatric Research Participation Questionnaire for Measuring Attitudes Toward Cancer Clinical Trials Among Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology, 2019, 8, 423-433.	1.3	6
50	Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 401-408.	0.8	19
51	Disparities in pediatric acute myeloid leukemia (AML) clinical trial enrollment. Leukemia and Lymphoma, 2019, 60, 2190-2198.	1.3	21
52	Hodgkin lymphoma patients have an increased incidence of idiopathic acquired aplastic anemia. PLoS ONE, 2019, 14, e0215021.	2.5	5
53	Significance of CNS 2 cerebrospinal fluid status postâ€induction in pediatric and adolescent patients with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2019, 66, e27433.	1.5	2
54	Comparable onâ€therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia. Pediatric Blood and Cancer, 2019, 66, e27583.	1.5	10

#	Article	IF	Citations
55	Mortality, Resource Utilization, and Inpatient Costs Vary Among Pediatric Heart Transplant Indications: A Merged Data Set Analysis From the United Network for Organ Sharing and Pediatric Health Information Systems Databases. Journal of Cardiac Failure, 2019, 25, 27-35.	1.7	5
56	Treatment and dose prioritization in early phase platform trials of targeted cancer therapies. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 475-491.	1.0	1
57	The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and nonâ€Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 684-688.	2.5	4
58	Trends in Inpatient and Intensive Care Resource Utilization after Chimeric Antigen Receptor T Cell Therapy for Pediatric Acute Lymphoblastic Leukemia from 2012-2019. Blood, 2019, 134, 61-61.	1.4	3
59	Poverty and survival in targeted immunotherapy clinical trials Journal of Clinical Oncology, 2019, 37, 10034-10034.	1.6	1
60	Text Message Responsivity in a 2-Way Short Message Service Pilot Intervention With Adolescent and Young Adult Survivors of Cancer. JMIR MHealth and UHealth, 2019, 7, e12547.	3.7	17
61	Home or Away from Home: A Multi-Institution Study Comparing Medical Outcomes, Patient Perspectives, and Health-Related Quality of Life for Outpatient Versus Inpatient Management after Chemotherapy for Pediatric Acute Myeloid Leukemia. Blood, 2019, 134, 379-379.	1.4	1
62	Comparing the Knowledge of Parents and Survivors Who Attend a Survivorship Clinic. Journal of Pediatric Oncology Nursing, 2018, 35, 56-64.	1.5	11
63	Cost comparison by treatment arm and centerâ€level variations in cost and inpatient days on the phase <scp>III</scp> highâ€risk B acute lymphoblastic leukemia trial <scp>AALL</scp> 0232. Cancer Medicine, 2018, 7, 3-12.	2.8	13
64	The role of peritoneal drainage in veno-occlusive disease in pediatric patients post hematopoietic stem cell transplant. Bone Marrow Transplantation, 2018, 53, 938-941.	2.4	1
65	A prospective study of family predictors of healthâ€related quality of life in pediatric brain tumor survivors. Pediatric Blood and Cancer, 2018, 65, e26976.	1.5	22
66	Hospital Variation in Intensive Care Resource Utilization and Mortality in Newly Diagnosed Pediatric Leukemia*. Pediatric Critical Care Medicine, 2018, 19, e312-e320.	0.5	10
67	Successful merging of data from the United Network for OrganÂSharing and the Pediatric Health Information System databases. Pediatric Transplantation, 2018, 22, e13168.	1.0	14
68	Proton therapy for pediatric head and neck malignancies. Pediatric Blood and Cancer, 2018, 65, e26858.	1.5	24
69	Molecular Testing for Oncogenic Gene Alterations in Pediatric Thyroid Lesions. Thyroid, 2018, 28, 60-67.	4.5	60
70	Resource utilization and toxicities after single versus tandem autologous stem cell rescue in highâ€risk neuroblastoma using a national administrative database. Pediatric Blood and Cancer, 2018, 65, e27372.	1.5	4
71	Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation. Infection Control and Hospital Epidemiology, 2018, 39, 797-805.	1.8	6
72	Opioid utilization among pediatric patients treated for newly diagnosed acute myeloid leukemia. PLoS ONE, 2018, 13, e0192529.	2.5	16

#	Article	IF	Citations
73	Relationship Between State-Level Google Online Search Volume and Cancer Incidence in the United States: Retrospective Study. Journal of Medical Internet Research, 2018, 20, e6.	4.3	71
74	Using administrative laboratory result data to describe adverse events Journal of Clinical Oncology, 2018, 36, e18698-e18698.	1.6	0
75	Classical Hodgkin Lymphoma Patients Have an Increased Incidence of Idiopathic Acquired Aplastic Anemia. Blood, 2018, 132, 5098-5098.	1.4	O
76	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	1.4	0
77	Evaluation of Hospital Admission Patterns in Children Receiving Treatment for Acute Lymphoblastic Leukemia: What Does a Typical Leukemia Experience Look like?. Blood, 2018, 132, 4763-4763.	1.4	2
78	Associates of Engagement in Adult-Oriented Follow-Up Care for Childhood Cancer Survivors. Journal of Adolescent Health, 2017, 60, 147-153.	2.5	28
79	Using electronic medical record data to report laboratory adverse events. British Journal of Haematology, 2017, 177, 283-286.	2.5	31
80	Adaptive Modeling: An Approach for Incorporating Nonlinearity in Regression Analyses. Research in Nursing and Health, 2017, 40, 273-282.	1.6	4
81	The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia. American Journal of Hematology, 2017, 92, 141-148.	4.1	29
82	Complications preceding early deaths in Black and White children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26712.	1.5	4
83	Cure modeling in real-time prediction: How much does it help?. Contemporary Clinical Trials, 2017, 59, 30-37.	1.8	4
84	Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2017, 102, e340-e343.	3.5	4
85	Association of Alternative Approaches to Normalizing Peritoneal Dialysis Clearance with Mortality and Technique Failure: A Retrospective Analysis Using the United States Renal Data System-Dialysis Morbidity and Mortality Study, Wave 2. Peritoneal Dialysis International, 2017, 37, 85-93.	2.3	4
86	Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research, 2017, 23, 1785-1796.	7.0	66
87	Radiotherapy-related outcomes in pediatric patients with atypical teratoid thabdoid tumor of the central nervous system. Journal of Radiation Oncology, 2017, 6, 153-160.	0.7	0
88	Creation of a pediatric mature B-cell non-Hodgkin lymphoma cohort within the Pediatric Health Information System Database. PLoS ONE, 2017, 12, e0186960.	2.5	5
89	Somatic HLA mutations expose the role of class l–mediated autoimmunity in aplastic anemia and its clonal complications. Blood Advances, 2017, 1, 1900-1910.	5.2	69
90	Comparing Analytic Methods for Longitudinal GWAS and a Case-Study Evaluating Chemotherapy Course Length in Pediatric AML. A Report from the Children's Oncology Group. Frontiers in Genetics, 2016, 7, 139.	2.3	2

#	Article	IF	Citations
91	Bortezomib Inpatient Prescribing Practices in Free-Standing Children's Hospitals in the United States. PLoS ONE, 2016, 11, e0151362.	2.5	5
92	Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at freeâ€standing paediatric hospitals in the United States. British Journal of Haematology, 2016, 174, 591-599.	2.5	14
93	Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transplant International, 2016, 29, 1017-1028.	1.6	34
94	Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database. Pediatric Blood and Cancer, 2016, 63, 901-907.	1.5	8
95	Model-based imputation of latent cigarette counts using data from a calibration study. International Journal of Methods in Psychiatric Research, 2016, 25, 112-122.	2.1	1
96	Early discharge as a mediator of greater <scp>ICU</scp> â€level care requirements in patients not enrolled on the <scp>AAML</scp> 0531 clinical trial: a Children's Oncology Group report. Cancer Medicine, 2016, 5, 2412-2416.	2.8	4
97	The impact of dexamethasone and prednisone on sleep in children with acute lymphoblastic leukemia. Supportive Care in Cancer, 2016, 24, 3897-3906.	2.2	26
98	Disrupted lymphocyte homeostasis in hepatitisâ€associated acquired aplastic anemia is associated with short telomeres. American Journal of Hematology, 2016, 91, 243-247.	4.1	11
99	Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals. Cancer, 2016, 122, 3394-3400.	4.1	8
100	Volume–Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 404-410.e1.	0.4	11
101	Neuroplastic Response After Radiation Therapy for Pediatric Brain Tumors: A Pilot Study. International Journal of Radiation Oncology Biology Physics, 2016, 95, 991-998.	0.8	6
102	Clonal evolution and clinical significance of copy number neutral loss of heterozygosity of chromosome arm 6p in acquired aplastic anemia. Cancer Genetics, 2016, 209, 1-10.	0.4	37
103	Carboplatin Rechallenge After Hypersensitivity Reactions in Pediatric Patients With Lowâ€Grade Glioma. Pediatric Blood and Cancer, 2016, 63, 21-26.	1.5	15
104	Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 223-229.e2.	0.4	12
105	Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2016, 34, 1537-1543.	1.6	47
106	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discovery, 2016, 6, 96-107.	9.4	144
107	Engagement and experience with cancer-related follow-up care among young adult survivors of childhood cancer after transfer to adult care. Journal of Cancer Survivorship, 2016, 10, 342-350.	2.9	48
108	Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening. British Journal of Ophthalmology, 2016, 100, 510-514.	3.9	30

#	Article	IF	CITATIONS
109	Relationship between sleep problems and psychological outcomes in adolescent and young adult cancer survivors and controls. Supportive Care in Cancer, 2016, 24, 539-546.	2.2	61
110	A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia. Cancer Medicine, 2015, 4, 1356-1364.	2.8	17
111	Comparison of administrative/billing data to expected protocolâ€mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1184-1189.	1.5	12
112	Comparison of in-patient costs for children treated on the AAMLO531 clinical trial: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2015, 62, 1775-1781.	1.5	21
113	Healthâ€related quality of life of adolescent and young adult survivors of childhood brain tumors. Psycho-Oncology, 2015, 24, 804-811.	2.3	31
114	Burden of Influenza-Related Hospitalizations and Attributable Mortality in Pediatric Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 290-296.	1.3	7
115	Emergence of clonal hematopoiesis in the majority of patients with acquired aplastic anemia. Cancer Genetics, 2015, 208, 115-128.	0.4	102
116	CASC15-S Is a Tumor Suppressor IncRNA at the 6p22 Neuroblastoma Susceptibility Locus. Cancer Research, 2015, 75, 3155-3166.	0.9	132
117	Suspension of accrual in phase II cancer clinical trials. Clinical Trials, 2015, 12, 128-138.	1.6	5
118	A Weibull multiâ€state model for the dependence of progressionâ€free survival and overall survival. Statistics in Medicine, 2015, 34, 2497-2513.	1.6	19
119	A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 528-528.	1.4	4
120	Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group. PLoS ONE, 2015, 10, e0143480.	2.5	16
121	Identification of patients with post-induction CNS 2 status and outcomes in acute lymphoblastic leukemia Journal of Clinical Oncology, 2015, 33, 10033-10033.	1.6	0
122	Accuracy of adverse event reporting on a phase III clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group Journal of Clinical Oncology, 2015, 33, 10028-10028.	1.6	0
123	Resource utilization (RU) and toxicities after carboplatin/etoposide/melphalan (CEM) and busulfan/melphalan (BuMel) for autologous stem cell rescue (ASCR) in high-risk neuroblastoma (HRNB) Journal of Clinical Oncology, 2015, 33, e21009-e21009.	1.6	0
124	Racial Disparities in Pediatric Acute Myeloid Leukemia during Induction. Blood, 2015, 126, 530-530.	1.4	0
125	Association of Weekend Admission With Hospital Length of Stay, Time to Chemotherapy, and Risk for Respiratory Failure in Pediatric Patients With Newly Diagnosed Leukemia at Freestanding US Children's Hospitals. JAMA Pediatrics, 2014, 168, 925.	6.2	24
126	Variation in Risk of Hospital-Onset Clostridium difficile Infection Across Â-Lactam Antibiotics in Children With New-Onset Acute Lymphoblastic Leukemia. Journal of the Pediatric Infectious Diseases Society, 2014, 3, 329-335.	1.3	18

#	Article	IF	CITATIONS
127	Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009. Pediatric Blood and Cancer, 2014, 61, 68-73.	1.5	11
128	Establishing a highâ€risk neuroblastoma cohort using the pediatric health information system database. Pediatric Blood and Cancer, 2014, 61, 1129-1131.	1.5	15
129	Competence in caregivers of adolescent and young adult childhood brain tumor survivors Health Psychology, 2014, 33, 1103-1112.	1.6	39
130	Evaluation of resources used during care of children with high-risk neuroblastoma (HR NBL) via merging of cooperative group trial data and administrative data Journal of Clinical Oncology, 2014, 32, 10069-10069.	1.6	3
131	Impact of weekend admission on hospital length of stay and organ failure in pediatric leukemia patients at free-standing U.S. children's hospitals Journal of Clinical Oncology, 2014, 32, 6598-6598.	1.6	0
132	Standardized costs and outcome in children treated with gemtuzumab on the AAML0531 trial: A report from the Children's Oncology Group Journal of Clinical Oncology, 2014, 32, 7086-7086.	1.6	0
133	Pediatric Hospital Volume and Induction Mortality in Pediatric Acute Lymphoblastic Leukemia (ALL). Blood, 2014, 124, 2653-2653.	1.4	0
134	ÂResource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. Blood, 2014, 124, 210-210.	1.4	0
135	Treatment Toxicity and Supportive Care Utilization in Children with Down Syndrome and Acute Lymphoid Leukemia at Free-Standing Pediatric Hospitals in the United States. Blood, 2014, 124, 553-553.	1.4	1
136	A Note on the Complementary Mixture Pareto II Distribution. Communications in Statistics - Theory and Methods, 2013, 42, 201-213.	1.0	0
137	Avascular Necrosis(AVN) and Surgical Intervention In Pediatric Acute Lymphoblastic Leukemia(ALL): A Retrospective Cohort Analysis From The Pediatric Health Information Systems (PHIS). Blood, 2013, 122, 1689-1689.	1.4	1
138	Accuracy Of Adverse Event Reporting Compared To Patient Chart Abstraction On a Phase III NCI-Funded Clinical Trial For Pediatric Acute Myeloid Leukemia: A Report From The Children's Oncology Group. Blood, 2013, 122, 931-931.	1.4	1
139	Single Nucleotide Polymorphism Array Analysis Of Bone Marrow Failure Patients Reveals Characteristic Patterns Of Genetic Changes. Blood, 2013, 122, 3710-3710.	1.4	0
140	A Bayesian approach for unplanned sample sizes in phase II cancer clinical trials. Clinical Trials, 2012, 9, 293-302.	1.6	6
141	Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric cancer patients Journal of Clinical Oncology, 2012, 30, 1504-1504.	1.6	0
142	Mortality and Resource Utilization in Children with De Novo Acute Myeloid Leukemia Treated with Chemotherapy and Gemtuzumab Ozogamicin in the United States. Blood, 2012, 120, 4283-4283.	1.4	0
143	Variability in Antifungal Use for Pediatric Acute Myeloid Leukemia At Children's Hospitals Across the United States. Blood, 2012, 120, 4278-4278.	1.4	1
144	Statistical analysis of daily smoking status in smoking cessation clinical trials. Addiction, 2011, 106, 2039-2046.	3.3	4

#	ARTICLE	IF	CITATION
145	Prediction of Individual Long-term Outcomes in Smoking Cessation Trials Using Frailty Models. Biometrics, 2011, 67, 1321-1329.	1.4	4
146	Dexrazoxane Use in Pediatric Patients with Acute Lymphoblastic or Myeloid Leukemia: Analysis of a National Cohort of Patients in the Pediatric Health Information Systems Database From 1999 to 2009. Blood, 2011, 118, 4242-4242.	1.4	15
147	Merging of Children's Oncology Group and Pediatric Health Information Systems Data to Determine Resource Utilization and Treatment Costs on AAML0531: A Report From the Children's Oncology Group. Blood, 2011, 118, 2617-2617.	1.4	O
148	Modeling smoking cessation data with alternating states and a cure fraction using frailty models. Statistics in Medicine, 2010, 29, 627-638.	1.6	16
149	Induction Mortality In Pediatric Acute Lymphoblastic Leukemia (ALL): a Retrospective Cohort Analysis From the Pediatric Health Systems Information (PHIS) Database, 1999–2009. Blood, 2010, 116, 3239-3239.	1.4	1